In agreement, CD19-targeting and sHVEM-producing CAR-T cells were more effective than those exclusively based on CD19-CAR-T in xenograft murine lymphoma models, since sHVEM released locally within the tumor avoided undesired systemic immunosuppressive effects [82]. This evidence concerns the gene CD19 and lymphoma.